{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:49:24Z","timestamp":1792619364105,"version":"4.5.0"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Peripheral Nervous Sys"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune\u2010mediated syndrome characterized by progressive muscle weakness and sensory impairment. Clinical similarities with other neuropathies can cause misdiagnoses and delayed diagnoses. Additionally, a large proportion of patients appropriately treated according to current guidelines still show residual disability. This real\u2010world study aimed to characterize a global cohort of patients with CIDP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross\u2010sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023. Neurologists and neuromuscular specialists reported on patient demographic and clinical characteristics at the time of the survey. Patients self\u2010reported treatment satisfaction, disease control, and health\u2010related outcome measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self\u2010reported data. Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%). Overall, initial misdiagnosis occurred in 37.2% of patients, with a median (interquartile range) diagnostic delay of 6.0 (3.0\u201312.0) months. Maintenance therapy was prescribed for 81.6% of patients, with corticosteroid use ranging from 25.7% in the United States to 80.0% in China. Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient\u2010reported scores were 62.1 (20.4) for I\u2010RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ\u20105D\u20105L.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Diagnostic delay and misdiagnoses were common occurrences across typical CIDP and variant CIDP. Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jns.70047","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:49:03Z","timestamp":1755582543000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real\u2010World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"first","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Borsi","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Ltd, A Johnson &amp; Johnson Company  High Wycombe UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Maria","family":"Boggia","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag SpA, A Johnson &amp; Johnson Company  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"de Courcy","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wright","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisam","family":"Karmous","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag, A Johnson &amp; Johnson Company  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Noel","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, A Johnson &amp; Johnson Company  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gary","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag, A Johnson &amp; Johnson Company  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Meyer zu H\u00f6rste","sequence":"additional","affiliation":[{"name":"University Hospital M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102014\u2010309697"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010179"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010020\u201000190\u20108"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010020\u201009998\u20108"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14796"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.11.031"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010020\u201000184\u20106"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001833"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797.pub4"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/pn\u20102021\u2010002991"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102024\u2010334165"},{"key":"e_1_2_10_14_1","unstructured":"European Medicines Agency \u201cVyvgart \u2013 opinion on variation to marketing authorisation \u201d2025 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/vyvgart."},{"key":"e_1_2_10_15_1","unstructured":"U.S. Food & Drug Administration \u201cFDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults \u201d2025 https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010treatment\u2010chronic\u2010inflammatory\u2010demyelinating\u2010polyneuropathy\u2010cidp\u2010adults."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27820"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010021\u201010677\u20105"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16399"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102015\u2010010352"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2279679"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1088"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318208824b"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20101\u201079"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687\u2010024\u201000769\u2010x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010012\u20100322\u20104"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010011\u20109903\u2010x"},{"key":"e_1_2_10_29_1","unstructured":"NICE \u201cPosition statement on use of the EQ\u20105D\u20105L value set for England (updated October 2019) \u201d2024 https:\/\/www.nice.org.uk\/about\/what\u2010we\u2010do\/our\u2010programmes\/nice\u2010guidance\/technology\u2010appraisal\u2010guidance\/eq\u20105d\u20105l."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2017.06.013"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.10.017"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","unstructured":"European Pharmaceutical Market Research Association (EphMRA) \u201cCode of Conduct \u201d2022 https:\/\/www.ephmra.org\/code\u2010conduct\u2010aer.","DOI":"10.21428\/b7013076.0eff92c3"},{"key":"e_1_2_10_33_1","unstructured":"US Department of Health and Human Services \u201cSummary of the HIPAA Privacy Rule \u201d2022 http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf."},{"key":"e_1_2_10_34_1","unstructured":"Health Information Technology (HITECH) \u201cHealth Information Technology Act. US Department of Health and Human Services \u201d2022 https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102020\u2010323615"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010020\u201010287\u20107"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010369.pub2"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1326874"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac054"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010024\u201007640\u20103"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.03.013"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198\u2010018\u20100955\u20105"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14907"},{"key":"e_1_2_10_44_1","unstructured":"Janssen Research & Development \u201cEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) \u201d2025 https:\/\/clinicaltrials.gov\/study\/NCT05327114."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000204596"},{"key":"e_1_2_10_46_1","unstructured":"Sanofi \u201cA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (VITALIZE) \u201d2025 https:\/\/clinicaltrials.gov\/study\/NCT06290141."},{"key":"e_1_2_10_47_1","unstructured":"Sanofi \u201cA Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE) \u201d2025 https:\/\/clinicaltrials.gov\/study\/NCT06290128."}],"container-title":["Journal of the Peripheral Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jns.70047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:49:56Z","timestamp":1758815396000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jns.70047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/jns.70047"],"URL":"https:\/\/doi.org\/10.1111\/jns.70047","archive":["Portico"],"relation":{},"ISSN":["1085-9489","1529-8027"],"issn-type":[{"value":"1085-9489","type":"print"},{"value":"1529-8027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"2025-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70047"}}